Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BMS and Merck & Co diabetes drug delayed by FDA
According to Bristol-Myers and Merck, the FDA wishes to address more fully the cardiovascular safety profile of the drug. The agency will therefore need data from ongoing trials,
According to Bristol-Myers and Merck, the FDA wishes to address more fully the cardiovascular safety profile of the drug. The agency will therefore need data from ongoing trials,
The partnership says that it “encourages” the study of neural crest stem cells as potential transplantable tissue for the repair of injury such as that sustained during traumatic
The acquisition includes the non-hormone birth control treatment ParaGard, which is approved for continuous use for the prevention of pregnancy for up to 10 years. The treatment was
The company has announced that it will eliminate the positions of senior vice president of clinical development and the vice president of regulatory affairs and compliance. Although, the
QR-333 is designed and formulated to significantly decrease the symptoms associated with diabetic peripheral neuropathy. The results of the first study conducted on hairless guinea pigs concluded that
Although some clinical activity was observed, the trial did not meet its endpoint for the number of patients with a response to therapy. However, Kosan will continue with
In the 58-patient randomized, double-blind, placebo-controlled clinical trial, conducted at two study centers in the US, the group consisting of 30 subjects who received ALGRX 4975 (100 micrograms)
The Apaf-1 (Apoptosis Protease Activating Factor 1) gene was discovered using large families from Utah that contain multiple cases of major depressive disorder. The evidence presented in the
The study will evaluate the safety of and immune response to AG-707 in up to 84 patients with herpes simplex virus type 2 (HSV-2), an infection affecting one
Tocosol paclitaxel has shown promising safety and anti-tumor activity in phase II clinical trials in a variety of solid tumors, and the product is currently in a phase